Funeral Pre Planning Provided in Athens, AL

For excellent service with funeral pre planning in the area of Athens, AL, please contact Madison Chapel Funeral Home. More information is available at http://www.madisonchapelfuneralhome.com/plan-ahead/overview.

Madison, United States - September 13, 2017 /PressCable/ —

The funeral directors of Madison Chapel Funeral Home offer their comprehensive funeral pre planning services to the residents of Athens, AL. There are numerous reasons why people should plan ahead, and pre planning offers many financial and emotional benefits. Making one’s own funeral plans is a simple process, it allows individuals to choose the manner in which they are commemorated, it reduces the burden on loved ones and it provides the opportunity to pre-fund one’s final arrangements and receive the advantages that doing so entails. Please learn more by visiting http://www.madisonchapelfuneralhome.com/plan-ahead….

It is not difficult to pre plan a funeral. One has the all the time needed to design a service while in a calm and rational state of mind. They can make the arrangements most fitting to their needs and desires by completing a brief form or by meeting with a professional staff member at Madison Chapel Funeral Home. A funeral pre plan can be made by anyone and at any stage in life. These arrangements can be altered at any time as the planner or his or her circumstances change.

Pre planning enables people to decide how they will be memorialized. Creating a written and detailed blueprint of one’s life celebration ensures that their wishes and preferences will be respected after they pass away. By including suggestions from one’s family in the plan, precious relationships and connections are strengthened.

After the demise of a loved one, surviving family members must endure many tasks and choices. This difficult process is made even more challenging because they are experiencing deep grief and confusion as a result of their tremendous loss. By making one’s own decisions regarding end-of-life arrangements in advance of need, one’s family is spared many responsibilities, allowing them more time and energy to devote to healing and reflection. Also, they will not question whether they are making the right decisions in paying tribute to the life and dealing with the physical remains. Any disagreements or arguments on these issues will be prevented, as the planner has made his or her selections clear.

Although pre-payment is not required to pre plan a funeral, it does protect the purchaser from price increases stemming from inflation and unanticipated factors. The loved ones left behind need not worry about the financial concerns of one’s funeral and will appreciate this reprieve from monetary obligations. The compassionate funeral directors of Madison Chapel Funeral Home would be honored to discuss the options available for pre-funding a funeral service.

Contact Info:
Name: Kevin Marsh
Organization: Madison Chapel Funeral Home
Address: 8521 U.S. 72, Madison, AL 35758, United States
Phone: +1-256-895-9900

For more information, please visit http://www.madisonchapelfuneralhome.com

Source: PressCable

Release ID: 238112

Latest News

EU charges Merck KGaA, GE, Canon of misleading merger info

Sep 25, 2017

By Foo Yun CheeBRUSSELS (Reuters) - General Electric , German drugmaker Merck KGaA , and Japan's Canon risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals.The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules.While the charges will not affect the EU approvals of the deals, they could lead to fines up to 1 percent of global revenue for Merck KGaA and General Electric, and up to...

Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion

Sep 25, 2017

By Sam NusseyTOKYO (Reuters) - Konica Minolta Inc said it was purchasing U.S. diagnostics company Ambry Genetics in a deal valued at up to $1 billion - an acquisition that marks a strategic shift for the Japanese firm's healthcare business as it seeks a leading position in precision medicine.The deal is the largest ever for the photocopier maker, which has been seeking to diversify away its office equipment business. It pulled out of cameras about a decade ago.Konica Minolta said its advanced imaging technology complemented privately held Ambry's genetic testing capabilities, with initial applications for combining the technologies seen in...

Oxford BioMedica wins big contract for Novartis cell therapy

Sep 25, 2017

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability.The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukemia that is expected to reach the market this year.A U.S. advisory panel will discuss the case for approving CTL019 at a meeting...

Novartis receives EU approval for Cosentyx label update

Sep 25, 2017

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday. (Reporting by Silke Koltrowitz)

FDA puts hold on Merck multiple myeloma trials after deaths

Sep 25, 2017

(Reuters) - Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.The rare setback for Keytruda sent Merck shares more than 1 percent lower.Merck has been on a roll with the medicine, jumping to the front of the pack of companies with new immuno-oncology drugs, particularly after Keytruda extended survival as an initial treatment for advanced lung cancer, by far the largest oncology market. Bristol-Myers...

Search
Top News
You May Need To Know

About Us

The Healthier Web delivers accurate and up-to-date health information through medical content and insights from experts. Feel the ‘ohm’ here in The Healthier Web.

Contact us: sales@thehealthierweb.com